<DOC>
	<DOC>NCT00163345</DOC>
	<brief_summary>The aim of this study is to evaluate the involvement of small airways in asthma, as determined by bronchial challenges, CT-scanning, and cellular markers of inflammation. Ciclesonide will be inhaled at one dose level once daily. The study duration consists of a baseline period (2 to 3 weeks) and a treatment period (5 to 6 weeks). The study will provide further data on safety and tolerability of ciclesonide.</brief_summary>
	<brief_title>Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 y) (BY9010/M1-131)</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>Main Written informed consent History of bronchial asthma FEV1 more than or equal to 60% of predicted Stable asthma Patients who are in good health with the exception of asthma Main Concomitant severe diseases, diseases expected to interfere with the outcome of the study, or diseases which are contraindications for the use of ICS COPD (i.e. chronic bronchitis or emphysema) and/or other relevant lung diseases causing alternating impairment in lung function Use of ICS 4 weeks before entry into the baseline period Pregnancy Intention to become pregnant during the course of the study Breast feeding Lack of safe contraception Use of other drugs not allowed Current smokers and exsmokers with more than or equal to 10 packyears</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Ciclesonide</keyword>
	<keyword>Small Airways</keyword>
</DOC>